Advanced search
Start date
Betweenand

Magnesium sulfate in pre-eclampsia with severe features: evaluating adequate use of medication and maternal and perinatal outcomes

Grant number: 18/08872-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): August 01, 2018
Effective date (End): July 31, 2019
Field of knowledge:Health Sciences - Medicine - Maternal and Child Health
Principal Investigator:Maria Laura Costa Do Nascimento
Grantee:Leonardo Bernardes de Amaro
Home Institution: Centro de Atenção Integral à Saúde da Mulher (CAISM). Hospital da Mulher Professor Doutor José Aristodemo Pinotti. Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

BACKGROUND: Hypertensive disorders of pregnancy, especially pre-eclampsia (PE), represent an important cause of maternal morbidity and mortality worldwide and mostly in middle and low-income countries. PE occurs in 3 to 5% of all pregnancies and in the presence of severe lfeatures, it is associated with worse outcomes. For treatment of PE with severe features, magnesium sulfate administration is the recommended medication, in order to avoid seizures (eclampsia) and should be used until 24h postpartum (which is the definitive treatment for PE). OBJECTIVE: To describe maternal and perinatal outcomes in women with PE with severe features treated with magnesium sulfate, and to detail the use of this medication (prescribing moment, triggering factor, average time of use) in our setting. METHODS: Cases will be initially identified through the medical computerized prescription system of the Hospital José Aristodemo Pinotti - CAISM/UNICAMP. All pregnant women that received magnesium sulfate in the last ten years (2008-2017) will be selected for medical chart review. Cases of PE will be further described, with an estimated sample of 600 cases. A descriptive analysis will be performed, including prevalence of all PE cases with severe features, socio-demographic characteristics, maternal and perinatal outcomes, as well as moment of use, triggering factor, average time of use, dose and need of other administration. Continuous variables will be presented as average (M) and standard deviation (DP). Categorical variables will be represented in percentage (%) of frequency.